- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00281827
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
Phase II Trial of Neoadjuvant Therapy With Carboplatin and Gemcitabine With Thalidomide in Patients With Stage II and IIIA Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving carboplatin and gemcitabine together with thalidomide before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying how well giving carboplatin and gemcitabine together with thalidomide works in treating patients who are undergoing surgery for stage II or stage III non-small cell lung cancer.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
OBJECTIVES:
Primary
- Determine the complete and partial response rates in patients with stage II or IIIA non-small cell lung cancer treated with neoadjuvant carboplatin, gemcitabine hydrochloride, and thalidomide.
Secondary
- Determine, preliminarily, the mechanism of action and activity of thalidomide against lung cancer.
- Determine the 1-year and 2-year survival of patients treated with this regimen.
- Determine the toxicity of this regimen in these patients.
- Determine the operative mortality of patients treated with this regimen.
OUTLINE: This is a pilot study.
Patients receive carboplatin intravenously (IV) over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and oral thalidomide once daily on days 1-21. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks after the completion of chemotherapy, patients with resectable tumors undergo surgical resection.
After completion of study treatment, patients are followed every 3 months for 2 years.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- University of Minnesota Cancer Center
-
Robbinsdale, Minnesota, Vereinigte Staaten, 55422-2900
- Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756-0002
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), including any of the following histologic subtypes:
- Squamous cell carcinoma
- Adenocarcinoma
- Large cell undifferentiated carcinoma
- Stage II or IIIA disease
- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral Computerized Axial Tomography (CT) scan
- No tumor involving the superior sulcus (e.g., Pancoast tumor)
- Karnofsky performance status 70-100%
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Creatinine ≤ 2 mg/dL
- Bilirubin < 2 mg/dL
- Aspartate aminotransferase (AST) < 3 times upper limit of normal
Exclusion Criteria:
Pregnant or nursing
- No nursing during and for ≥ 4 weeks after completion of study treatment
- Positive pregnancy test
- Fertile female patients must use 2 effective methods of contraception 4 weeks before, during, and for 4 weeks after completion of study treatment
- Fertile male patients must use effective barrier contraception during and for 4 weeks after completion of study treatment
- Blood, sperm, or ova donation during study treatment
- Post obstructive pneumonia
- Other serious infection or medical illness that would preclude study participation
- Other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other malignancy that is unlikely to affect survival for the next 3 years
- Less than 5 years since prior resection of lung disease
- Prior systemic chemotherapy or radiotherapy for non-small cell lung cancer (NSCLC)
- Other concurrent chemotherapy or radiotherapy
- Concurrent hormonal therapy or immunotherapy
- Other concurrent anticancer therapy
- Other concurrent investigational agents
- Concurrent participation in another clinical study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Treatment Arm
Chemotherapy treatment (carboplatin, gemcitabine and thalidomide) every 21 days for 3 courses.
|
Day 1 of Cycles 1, 2 and 3 - intravenously (IV) 30 minutes (Area Under the Curve = 5.5)
Andere Namen:
Days 1 and 8 of Cycles 1, 2 and 3 - 30 minute IV, 1000 mg/m2.
Andere Namen:
Oral administration: Cycle 1 - Day 1 50 mg, Day 2 100 mg, Day 3 150 mg, Day 4 and continuing until end of study treatment 200 mg.
Andere Namen:
Resection - between 2 and 6 weeks following last dose of chemotherapy.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Patients Reporting Clinical Response
Zeitfenster: At end of 3 -21 day cycles of treatment
|
Objective clinical response measuring using tumor assessments: Complete Response (CR) = disappearance of all target and non-target lesions and normalization of tumor marker level, if applicable.
Pathological Complete Response (PCR) = No viable tumor cells in specimen determined by light microscopy.
Partial Response (PR) = at least 30% decrease in the sum of longest diameter of target lesions from baseline.
Progressive Disease (PD) = at least 20% increase in the sum of longest diameters of target lesions from baseline or new lesions.
Stable Disease (SD) = Neither PR or PD.
|
At end of 3 -21 day cycles of treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Patients Disease-free at 1 Year
Zeitfenster: 1 year
|
Calculated from date of enrollment to date of recurrence or death, whichever came first
|
1 year
|
Number of Patients Disease-free at 2 Years
Zeitfenster: 2 Years
|
Calculated from date of enrollment to date of recurrence or death, whichever came first
|
2 Years
|
Number of Patients Alive at 1 Year (Survival)
Zeitfenster: 12 Months
|
Participants who were alive at one year from date of enrollment .
|
12 Months
|
Number of Patients Alive at 2 Years (Survival)
Zeitfenster: 24 Months
|
Participants who were alive at 2 years from date of enrollment.
|
24 Months
|
Number of Patients Alive at 56 Months (End of Study)
Zeitfenster: Up to 56 months
|
Patients alive from date of enrollment to date of death or censored at date of last contact (Overall Survival).
|
Up to 56 months
|
Mitarbeiter und Ermittler
Ermittler
- Studienstuhl: Arkadiusz Dudek, MD, Masonic Cancer Center, University of Minnesota
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen der Atemwege
- Neubildungen
- Lungenkrankheit
- Neubildungen nach Standort
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Lungentumoren
- Karzinom, nicht-kleinzellige Lunge
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Enzym-Inhibitoren
- Antimetaboliten, antineoplastisch
- Antimetaboliten
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Angiogenese-Inhibitoren
- Angiogenese-modulierende Mittel
- Wuchsstoffe
- Wachstumshemmer
- Antibakterielle Mittel
- Leprostatische Mittel
- Gemcitabin
- Carboplatin
- Thalidomid
Andere Studien-ID-Nummern
- 2002LS013
- LILLY-X-382 (Andere Kennung: Eli Lilly)
- 0202M17981 (Andere Kennung: IRB, University of Minnesota)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Lungenkrebs
-
Hal C CharlesAbgeschlossenKonstriktive Bronchiolitis | Irak-Afganistan War Lung Injury SyndromeVereinigte Staaten
-
Joseph MccuneEunice Kennedy Shriver National Institute of Child Health and Human Development... und andere MitarbeiterBeendetLupus erythematodes, systemisch | Systemische Vaskulitis | Lungenerkrankung mit systemischer Sklerose | Isolierte Angiitis des zentralen Nervensystems | Lung Disease Interstitial DiffusVereinigte Staaten
Klinische Studien zur carboplatin
-
Eisai Inc.AbgeschlossenKrebsVereinigte Staaten, Österreich, Indien
-
Samyang Biopharmaceuticals CorporationAbgeschlossen
-
National Cancer Institute (NCI)AbgeschlossenBrustkrebs | EierstockkrebsVereinigte Staaten
-
AkesoRekrutierungFortgeschrittener plattenepithelialer nicht-kleinzelliger LungenkrebsChina
-
Rennes University HospitalAbgeschlossenEierstockkrebsFrankreich
-
Barts & The London NHS TrustUniversity College London HospitalsAbgeschlossenMetastasierendes SeminomVereinigtes Königreich
-
North Bristol NHS TrustZurückgezogenGlioblastoma multiformeVereinigtes Königreich
-
Nippon Kayaku Co., Ltd.AbgeschlossenFortgeschrittene solide Tumoren | Metastasierter dreifach negativer BrustkrebsVereinigte Staaten
-
Myrexis Inc.UnbekanntPhase-1-Studie zu MPC-6827 und Carboplatin bei rezidivierendem/rezidiviertem Glioblastoma multiformeGlioblastoma multiformeVereinigte Staaten
-
The First Affiliated Hospital of Guangzhou Medical...UnbekanntNicht-kleinzelligem LungenkrebsChina